Vaxcyte Inc. Common Stock vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $28.31 (market cap $950.14M). The key difference: Vaxcyte Inc. Common Stock is far larger — about 11.1× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Roundhill Innov-100 0DTE Covered Call Strat ETF for 59 Days on average.
| PCVX | QDTE | |
|---|---|---|
Market Cap | $10.51B | $950.14M |
Volume | 2,644,694 | 170,009 |
Sector | Health | Income / Options Overlay |
52-Week High | $73.82 | $36.60 |
52-Week Low | $40.32 | $26.85 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $9.14B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QDTE (Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF) trades at $29.29, down 0.14% with a bearish technical signal. The fund provides weekly distributions but faces criticism for yield sustainability and NAV erosion. Recent dividend payments have declined from $0.28 to $0.11, reflecting volatility compression. Technical indicators show mixed signals with neutral oscillators but bearish moving averages.
Outlook remains cautious due to structural concerns about return-of-capital distributions and underperformance in bull markets. The 24-31% yield appears unsustainable, with the fund sacrificing upside potential. Key risks include NAV decay, fee drag, and dependence on market volatility. Analyst sentiment has turned neutral to negative on the strategy's long-term viability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →